Three Primary Tumors Including EGFR-mutated Non-Small Cell Lung Cancer as First Presentation in Patient With Li-Fraumeni Syndrome

Clin Lung Cancer. 2021 Jan;22(1):e116-e121. doi: 10.1016/j.cllc.2020.09.006. Epub 2020 Sep 18.

Authors

Arjan Gower¹, Jong Kim², Kellie Spector³, Daniella Menashe⁴, Eric Vail², Ronald Natale⁴

Affiliations

¹ Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA. Electronic address: Arjan.gower@cshs.org.
² Department of Pathology, Cedars Sinai Medical Center, Los Angeles, CA.
³ Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA.
⁴ Division of Medical Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA.

PMID: 33172777
DOI: 10.1016/j.cllc.2020.09.006

No abstract available

Keywords: EGFR; Li-Fraumeni syndrome; NSCLC; Osimertinib; TP53 R337H.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adenocarcinoma of Lung / etiology
Adenocarcinoma of Lung / pathology*
Adenocarcinoma of Lung / therapy
Adult
ErbB Receptors / genetics
Female
Germ-Line Mutation
Humans
Li-Fraumeni Syndrome / complications*
Lung Neoplasms / etiology
Lung Neoplasms / pathology*
Lung Neoplasms / therapy
Mutation*
Prognosis
Tumor Suppressor Protein p53 / genetics
Uterine Neoplasms / etiology
Uterine Neoplasms / pathology*
Uterine Neoplasms / therapy

Substances

TP53 protein, human
Tumor Suppressor Protein p53
EGFR protein, human
ErbB Receptors